| Stem cell modifications |
|
|
|
| Enzyme/prodrug therapy |
Glioma |
NSCs (retroviral transduction with CD) |
[16, 26] |
| NSCs (baculoviral transduction with HSV-TK) |
[29] |
| MSCs (lentiviral and retroviral transduction with S-TRAIL and HSV-TK) |
[27] |
| MSCs (retroviral transduction with CD ) |
[25] |
| Colon adenocarcinoma |
NSCs (adenovirus transduction with a rabbit CE) |
[26] |
| Metastatic lung cancer and primary lung cancer |
NSCs (engineered to express CE) |
[9] |
| Secreted agents |
Glioma |
NSCs (retrovirus transduction with IL-4 ) |
[26] |
| NSCs (adenovirus transduction with TRAIL) |
[26] |
| NSCs (encapsulated in sECM after being engineered to express S-TRAIL) |
[32] |
| Breast cancer brain metastases |
NSCs (lentivirus transduction with anti-HER2Ab) |
[7] |
| Breast cancer |
MSCs (engineered to over express IFN-beta) |
[33] |
| Viral therapy |
Glioma |
NSCs (infected with CRAd-S-pk7) |
[35, 67] |
| MSCs (loaded with oHSV ) |
[38] |
| Hepatocellular carcinoma |
MSCs (infected with measles virus) |
[37] |
| Nanoparticle carriers |
Solid tumor |
NSCs (loaded with gold nanorods) |
[40] |
| Glioma |
MSCs (loaded with poly-lactic acid nanoparticles and lipid nanocapsules) |
[41] |
| MSCs (loaded with nanoparticles) |
[42] |
| Regenerative medicine |
Hematologic malignancies |
HSCs (allogeneic transplantation) |
[44] |
| Liver disease |
iPSCs (engraftment of patient-specific iPSCs) |
[45, 46] |
| Immunotherapy |
Solid tumor |
HSCs (induction of graft vs. tumor effect ) |
[48] |
| Lymphomas |
HSCs (allogeneic transplantation) |
[49] |
| iPSCs (generate T cells) |
[53] |
| Melanoma |
HSCs (genetically engineered HSCs to generate antigen-specific CD8 T cells) |
[51] |
| Targeting CSCs |
Glioma |
HSCs (modifying the proteome profile of HSCs ) |
[57] |
| Anticancer drug screening |
/ |
cancer tissue-derived iPSCs (provide cellular targets) |
[59]. |
